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ABSTRACT
Introduction: Knee osteoarthritis is one of the
leading causes of disability in the world.
Intra-articular hyaluronic acid (IA-HA) is a
treatment modality that provides a minimally
invasive treatment option for the management
of osteoarthritis-related symptoms. This study
examined the current and potential economic
impact of using a biologically derived, high
molecular weight hyaluronic acid preparation
(Euflexxa) on the US population for the
management of knee osteoarthritis.
Methods: A model was developed to estimate
the total number of patients with symptomatic
knee osteoarthritis in the US in 2015,
distributed by Kellgren–Lawrence (K–L) grade,
and the number of people living with total knee
arthroplasty (TKA). The potential utility of
Euflexxa was applied to this model population
to determine the current and potential impact
of the treatment as the total number of quality
adjusted life years (QALY) saved within the US
population.
Results: There are approximately 12 million
people currently suffering from symptomatic
knee osteoarthritis in the US, and approximately
5 million living with TKA. It was estimated that,
with a target treatment group of K–L grades 2–3,
there are approximately4millionpatients eligible
for treatment with a high molecular weight
intra-articular hyaluronic acid injection. With
current use, it is estimated that Euflexxa can save
36,730 QALY/year among theUSpopulation, and
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has the potential to save an additional
369,181 QALY/year if used by all eligible patients.
Conclusions: This study demonstrates that
more widely used, biologically derived, high
molecular weight IA-HAs, such as Euflexxa,
have the potential to save a substantial
number of QALYs among the US population
with symptomatic knee osteoarthritis.
Funding: Ferring Pharmaceuticals Inc.
Keywords: Economic; Euflexxa; Hyaluronic
acid; Knee; Orthopaedics; Osteoarthritis
INTRODUCTION
Knee osteoarthritis (OA) is a chronic, progressive
disease that continues to be one of the leading
causes of disability among active patients in the
USA. Knee OA results in a decrease in quality of
life for those suffering from the disease, as well
as a large financial burden on health care
systems and society [1, 2]. The prevalence of
symptomatic knee OA in the USA was estimated
to be 9.9 million in 2010, and it is estimated that
among older adults in the USA, there are over 10
million quality of life years lost annually
because of knee OA [3, 4].
A number of treatment methods are
available for managing the symptoms of knee
OA. Non-surgical treatments may incorporate
changes in diet and exercise, ambulatory aids,
simple analgesics, and non-steroidal
anti-inflammatory drugs (NSAIDs), while more
invasive treatments may include intra-articular
injections and surgical interventions like total
knee arthroplasty (TKA). Many patients
diagnosed with OA may have comorbidities
precluding them from some of the available
treatment options [5]. There are also patients
that may not demonstrate an adequate response
to non-surgical treatments and are unwilling or
medically unsuitable to undergo surgical
interventions [6]. Experts argue that it is
essential to prolong the period of time
between the decline of conservative treatment
efficacy and surgical intervention, as having
TKA at a younger age may increase the
likelihood of requiring a revision, leading to
increased costs and possible complications [7].
It is therefore important to consider treatment
options available that may alleviate symptoms
related to knee OA and delay the need for
primary TKA in order to reduce the likelihood of
requiring a revision TKA.
The use of intra-articular hyaluronic acid
(IA-HA) as a treatment method for knee OA
presents a non-surgical option for symptom
relief which may provide better results than
other conservative treatment options [8, 9].
Evidence also suggests that the use of IA-HA
preparations may safely delay the time to
arthroplasty [10, 11]. The IA-HA preparation
Euflexxa (1% sodium hyaluronate) has been
shown to be a cost-effective method of treating
the symptoms associated with knee OA;
however, the current and potential economic
impact of this form of treatment on the US
population has yet to be determined [12].
The purpose of this study is to determine the
current and potential impact that a biologically
derived high molecular weight IA-HA (Euflexxa)
may have on quality adjusted life years (QALY)
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Study Scope and Model Generation
We modelled the total number of patients in
the USA (2015) with symptomatic knee OA,
distributed across Kellgren–Lawrence (K–L) OA
severity grades, and the current number of
patients with TKA. Using these estimates, we
projected the total number of eligible patients
who may benefit from the use of Euflexxa versus
conventional care in the USA.
The model was developed to provide an
estimate for the prevalence of symptomatic
knee OA in the USA in 2015. Estimates for the
prevalence of symptomatic knee OA in the USA
were obtained from the American Academy of
Orthopaedic Surgeons (AAOS) [3], and estimates
on the incidence of knee OA, prevalence of
TKA, and incidence of TKA were obtained from
the published literature [13–15] (Table 1). The
portion of the population who have undergone
a TKA was omitted from the model, given that
they have already received definitive knee OA
treatment and would no longer be eligible to
benefit from an IA-HA injection. As incidence
data was sourced from 1995, the prevalence per
100,000 person/years was taken and adjusted
for the age and sex distribution for 2015 [13]. It
was estimated that there were 9.9 million
people with symptomatic knee OA in the USA
in 2010, and that the annual incidence of
symptomatic knee OA in the US is
approximately 770,000 (Table 1).
The distribution of patients with knee OA by
K–L severity grades was obtained from a large
observational study on knee OA involving 3021
people surveyed in the US population [16]. The
majority of studies examining IA-HA involved
participants with K–L grades of 2–3, so the
percentage of the symptomatic OA population
with K–L grades 2 and 3 was calculated to
determine the total number of patients eligible
to benefit from IA-HA injections. Patients across
all K–L levels who had not received a TKA or
were currently using IA-HA were considered
eligible to receive appropriate conventional
care. The current use of Euflexxa and other
IA-HA products was obtained through the IMS
claims data for 2014 [17].
The mortality rate corresponding to the
demographics of the model population was
used, under the previously validated
assumption that mortality amongst the OA
population is similar to that of the general US
population [18–20]. Data on utility scores for
the healthy US population was obtained from
the literature [21].
The changes in health state of patients
receiving treatment was reported in terms of a
utility score, represented in QALYs, a frequently
used quality of life measurement in health
economic analyses. QALYs are determined by
using utility values that represent desired health
states which, for a single patient, vary from 0
(indicating death) to 1 (indicating perfect
health) [22]. In order to determine the impact
of a treatment, the number of eligible patients
for the treatment was multiplied by the increase
in utility score resultant from that treatment.
Total QALYs saved within the population of
patients with symptomatic knee OA in the USA
for 1 year was calculated for the following three
scenarios: (1) all eligible patients with knee OA
receiving no treatment versus current Euflexxa
use; (2) current Euflexxa use versus use in all
eligible patients with kneeOA; and (3) all eligible
patients with knee OA receiving no treatment
versus all eligible patients receiving Euflexxa.
OA Prevalence and TKA Prevalence
Calculations
The prevalence of symptomatic knee OA in the
USA for the year 2015 was estimated according
to the formula
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f 5 xð Þ ¼ xþ yð Þ  xþ yð Þ  z
where x is the 2010 symptomatic knee OA
prevalence, y is the symptomatic knee OA
incidence, and z is the US death rate for adults
over 35.
A similar formula was used to estimate the
prevalence of TKA in the US population:
f 2 að Þ ¼ aþ bð Þ  aþ bð Þ  z
where a is the 2013 TKA prevalence, b is the TKA
incidence, and z is the US death rate for adults
over 35.
Both of these formulas are nested formulas,
where the number of times the formula is
nested corresponds to the superscript number.
The nested formula takes the preliminary
prevalence, adds the incidence, and subtracts
the death rate to gain the prevalence for the
following year. This new prevalence is then the
starting point for the next iteration of the
formula, which is repeated for the number of
times specified.
Treatment
The treatment option examined in this study is
the high molecular weight IA-HA injection
Euflexxa. In a randomized controlled trial (the
FLEXX trial), Altman et al. examined this
preparation over two courses of three injections,
with 6 months between each course of treatment
[23]. As a comparator, we used appropriate
Table 1 US OA demographic values
Variable Past estimates (year) 2015 estimate
US symptomatic knee OA prevalence 9,900,000 (2010)a 12,338,273
US OA incidence 768,494 (1995)b 605,598
US TKA prevalence 4,000,000 (2013)c 5,240,455
US TKA incidence 671,374 (2012)d –
US death rate in adults[35 1.026% (2007)e –
K–L grade 1 30.0% (2009)f 2,130,382
K–L grade 2 27.3% (2009)f 1,939,724
K–L grade 3 29.2% (2009)f 2,074,428
K–L grade 4 13.4% (2009)f 953,283
Total eligible patients – 4,014,153
Current Euﬂexxa use 276,168 (2014)g 276,168
Current other IA-HA use 962,185 (2014)g 962,185
Total eligible non-HA users – 3,051,968
a AAOS, 2010
b Oliveria, 1995 [13]
c Weinstein, 2013 [14]
d Healthcare Cost and Utilization Project, 2015 [15]
e Centers for Disease Control and Prevention, 2015 [18]
f Multicenter Osteoarthritis Study, 2010 [16]
g IMS, 2014 [17]
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conservative care (henceforth referred to as
‘‘appropriate care’’), which was defined as all
non-IA-HA treatments (NSAIDS and other
analgesics, physiotherapy, weight loss,
ambulatory aids), and abstracted the data from a
randomizedcontrolled trialbyTorranceetal. [24].
Utility Score Calculations
Baseline and treatment utility scores for
Euflexxa over the course of a year were
abstracted from Hatoum et al. [12], plotted,
and the area under the curve between the two
treatments was calculated for the total QALYs
gained over 1 year. To model those receiving no
treatment, baseline scores were extrapolated
over a year with the assumption that their
condition would neither worsen nor improve.
Utility score information for appropriate care
was obtained from Torrance et al., which
compared baseline utility scores to scores
following one year of appropriate care [24].
Utility scores for the US population across
different age groups were abstracted from
previously published EQ-5D data [22]. Since
patients who receive IA-HA as a treatment
method also receive aspects of appropriate care
in addition to the injections, the QALY of
appropriate care was subtracted from the
QALY of the IA-HA preparation to account for
gains potentially attributed to the use of
appropriate care.
Economic Impact Calculation
The current and potential impact of each
treatment was calculated by multiplying the
utility score of the treatment for one person
over the course of a year by the number of
people currently using, or eligible to use the
treatment, respectively. The current impact of
Euflexxa was determined by comparing the
current use of Euflexxa to no use. The
potential impact of Euflexxa was determined
by modelling the utility of all eligible patients
using Euflexxa and comparing it to the
modelled utility of both current use and no use.
Sensitivity Analysis
Sensitivity analysis was conducted to evaluate
the robustness of the results, and to provide
confidence intervals to account for potential
variation in both the population of eligible
patients and the efficacy of the treatment. This
was evaluated by performing a two-way
sensitivity analysis by increasing and decreasing
both the number of eligible patients and the
utility score of Euflexxa by ±20%.
Sensitivity analysis was also performed to
provide insight into potential uncertainties in
certain inputdomains. The currentuseof Euflexxa
was determined from IMS claims data in 2014;
however, as this value may have either increased
or decreased in 2015, a two-way sensitivity
analysis was performed on the current use of
Euflexxa. In addition, there is some uncertainty as
towhether themortality rateof personswithOA is
similar to or higher than that in the general
population [18–20, 25]. In order to consider this
uncertainty, a two-way sensitivity analysis was
performed adjusting the mortality rate.
RESULTS
Knee OA Prevalence in the USA
The estimate for the number of people with
symptomatic knee OA in the USA in 2015 is
therefore approximately 12.3 million. The
model estimated the prevalence of patients
who have received a TKA in the USA to be
approximately 5.2 million, which left 7.1
million people in the USA with symptomatic
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knee OA who have not received a TKA. The
number of patients with K–L 2–3 OA was
determined to be 4.0 million, or roughly 32%
of the population who have symptomatic knee
OA [17]. To determine the number of patients
eligible for Euflexxa injection, the number of
patients receiving other forms of IA-HA were
subtracted (n = 962,185), leaving 3.0 million
eligible patients, of which 276,168 are currently
using Euflexxa [18].
Utility Scores
A calculation of the area under the curve
between baseline and treatment over 1 year for
the use of Euflexxa indicated that there was
0.163 QALYs gained per year per person, while
the effectiveness of appropriate care was
determined to be 0.03 QALYs gained per
person per year [24]. The QALYs gained per
person per year for Euflexxa when accounting
for the concomitant use of appropriate care was
therefore considered to be 0.133 QALYs.
Current Impact of Euflexxa
Figure 1 shows the 1-year QALY for a healthy
individual, an OA patient receiving no
treatment, and an OA patient receiving
Euflexxa, and for a 62-year-old (mean age
of the FLEXX trial treatment group) [23].
The current estimate for the number of
QALYs saved by Euflexxa is 36,730 QALY/
year when comparing current use to no use
(Table 2).
Potential Impact of Euflexxa
If all 3.0 million eligible symptomatic knee OA
patients were to use Euflexxa, then an
additional 369,181 QALY/year could be saved
in addition to the current impact of Euflexxa.
If all eligible patients were treated with
Euflexxa, there would be a potential
405,911 QALY/year saved, when compared to
not treating any eligible patients with Euflexxa
(Table 2).
Fig. 1 QALY for healthy individual, OA patient receiving no treatment, and OA patient receiving Euﬂexxa (age 62)
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Comparison to Appropriate Care
The model determined that 6.2 million patients
were eligible for appropriate care. The total
number of QALY saved if all eligible patients
were to use appropriate care was determined to
be 185,074 QALY/year, less than half of the
impact of Euflexxa.
Sensitivity Analysis
When evaluating the current use of Euflexxa,
the modelled value of 36,730 QALY/year saved
ranged from 23,507 to 52,891 QALY saved,
when both the number of eligible patients and
the utility score of Euflexxa were adjusted by
±20% (Table 3). The range of values for the
additional QALY/year saved, if all potential
patients used Euflexxa, was
287,999–450,363 QALY/year for a potential
total range of 324,729–487,094 QALY saved
per year. The sensitivity analysis for the
potential maximum QALY/year saved by
appropriate care revealed that the impact
ranged from 118,447 to 266,506 QALY/year.
The sensitivity analysis examining the
current use of Euflexxa determined that for
the modelled 276,168 patients the lower and
upper limits of the sensitivity were 220,934 and
331,401, respectively. These limits
Table 2 Impact of Euﬂexxa
Variable Euﬂexxa Appropriate care
Baseline utility 0.482 0.46
Post treatment utility 0.645 0.51
QALY gained 0.163 0.03
Current QALY gained per year (current use–no use) 36,730 –
Potential QALY gained per year (maximum use–no use) 405,911 185,074
Potential additional QALY gained per year (maximum use–current use) 369,181 –





QALY Impact QALY Impact
Euﬂexxa Current use High 331,401 0.1596 52,891 0.1064 35,261
Low 220,934 35,261 23,507
Additional High 3,330,960 531,621 354,414
Low 2,220,640 354,414 236,276
Maximum High 3,662,362 584,512 389,675
Low 2,441,574 389,675 259,783
Appropriate care Maximum High 7,402,964 0.036 266,506 0.024 177,671
Low 4,935,309 177,671 118,447
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corresponded to the originally modelled
36,730 QALY/year adjusting to 44,076 QALY/
year for the upper limit and 29,384 QALY/year
for the lower limit. When examining mortality
rate, it was found that a 20% decrease in the
mortality rate increased the number of persons
with symptomatic knee OA to 12,454,377
corresponding to 414,645 QALY/year saved,
while an increase in the mortality rate led to a
decrease in the persons with symptomatic knee
OA to 122,223,078 and an impact of
397,247 QALY/year saved.
DISCUSSION
The purpose of this study was to evaluate the
current and potential impact of a biologically
derived, high molecular weight IA-HA
preparation (Euflexxa) on the US population
with symptomatic knee OA. Our model found
that Euflexxa currently saves 36,730 QALY/year,
and has the potential to save an additional
369,181 QALY/year if it was to be more widely
administered.
Several studies have looked at the
cost-effectiveness of various treatments
[2, 12, 24], the lifetime medical costs of
treatments [26, 27], and the impact of OA
treatments in European countries [28]. To our
knowledge, this is the first study to measure the
current and potential impact of a symptomatic
knee OA treatment modality with respect to the
total number of QALYs saved per year across the
entire US population. The lack of literature
demonstrating the impact of other treatment
methods makes it difficult to compare the
impact of Euflexxa to other treatment
modalities; however, we were able to compare
our intervention to appropriate care, which
covers all other forms of non-operative
treatment.
Previous literature has shown that treatment
of knee osteoarthritis with IA-HA, and
specifically with biologically derived
hyaluronic acid (Bio-HA), is a cost-effective
treatment option over appropriate care
[12, 24]. The results of this study also
demonstrate a difference in the potential
impact of these two treatment methods. While
appropriate care had a larger eligible patient
base compared to Euflexxa (50% versus 34% of
all symptomatic knee OA patients, respectively),
Euflexxa still demonstrated an overall larger
impact on the symptomatic knee OA
population by more than double
(405,911 QALY/year to 185,074 QALY/year,
respectively).
Several assumptions were made within this
study which may be limitations of the accuracy
of the model. The first assumption is that only
patients with K–L 2 or 3 are eligible for the use
of Euflexxa. It is possible for patients with K–L 1
and 4 to be prescribed IA-HA, and this
assumption may underestimate the total
number of patients who may benefit from the
use of the treatment. Second, when comparing
Euflexxa to appropriate care, two different
studies were used, involving patients from
different regions and at different times,
meaning that the patient populations were not
the same and which may result in some
unwanted variation. In addition, the health
utility index for patients receiving either
Euflexxa or appropriate care was derived from
different preference measures than the healthy
population. This derivation from different
initial measures may lead to some potential
differences between the QALY scores between
the patients with symptomatic knee OA and the
healthy population. The utility score data from
Hatoum et al. [12] included data from both the
FLEXX trial and extension trial, although the
extension was an open label investigation. This
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creates a potential limitation, as the open label
extension trial data may be subject to bias.
Finally, there is a lack of information in the
current literature regarding suboptimal
adherence to an IA-HA injection regimen. For
this reason, we used the available evidence for
Euflexxa use, which demonstrated no issues
with adherence; however, this may not be the
case in clinical scenarios.
The present study is strengthened by the
sensitivity analysis, which examines potential
variation in both the population of eligible
patients and the efficacy of the treatment
method. The two-way analysis provides a
range of the current and potential impacts on
the US population based on up to a 20%
increase or decrease in both the eligible
population and the utility score of the
treatment method.
CONCLUSION
This study has shown that, if more widely used,
a biological fermentation-derived, high
molecular weight IA-HA preparation, such as
Euflexxa, has the potential to save substantial
QALY per year within the USA; this is more than
twice as much as appropriate care. Further
studies examining the impact of additional
treatment methods on the US population will
allow further comparison between OA
treatment strategies.
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